Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer

Cancer Research

Volumn 73, Issue 13, 2013, Pages 3927-3937

  Ma, Ying ^a   Hwang, Rosa F ^a   Logsdon, Craig D ^a,b   Ullrich, Stephen E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CROMOGLYCATE DISODIUM; INTERLEUKIN 13; PLACEBO; PLERIXAFOR; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2; TRYPTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL COMMUNICATION; CELL DEGRANULATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; INTERLEUKIN-13; MAST CELLS; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; RECEPTORS, CXCR4; STROMAL CELLS; TRYPTASES; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880074843     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4479     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60: 277-300.
2. Fleshman J. Pancreatic cancer: a rare tumor with a devastating health toll. Rare Tumors 2010;2: e52.
3. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007;101: 887-907.
4. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350: 1200-10.
5. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324: 1457-61.
6. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer 2005;5: 459-67.
7. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67: 9518-27.
8. YenTW, AardalNP, BronnerMP, ThorningDR, SavardCE, Lee SP, et al. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 2002;131: 129-34.
9. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68: 918-26.
10. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60: 861-8.
11. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21: 418-29.
12. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62: 112-20.
13. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004;29: 179-87.
14. Xu Z, Vonlaufen A, PhillipsPA, Fiala-Beer E, Zhang X, Yang L, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 2010;177: 2585-96.
15. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008;68: 2085-93.
16. Ribatti D, Crivellato E. The controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol 2009;275: 89-131.
17. Choi KL, Claman HN. Mast cells, fibroblasts, and fibrosis. New clues to the riddle of mast cells. Immunol Res 1987;6: 145-52.
18. Cai SW, Yang SZ, Gao J, Pan K, Chen JY, Wang YL, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 2010;149: 576-84.
19. Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 2010;16: 2257-65.
20. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y, et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res 2011;17: 7015-23.
21. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 1996;148: 1763-70.
22. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000;157: 1623-31.
23. Butterfield JH, Weiler DA, Hunt LW, Wynn SR, Roche PC. Purification of tryptase from a human mast cell line. J Leukoc Biol 1990;47: 409-19.
24. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 2003;27: 677-82.
25. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 2007;22: 1304-9.
26. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140: 323-34.
27. Byrne SN, Limon-Flores AY, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction of immune suppression. J Immunol 2008; 180: 4648-55.
28. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44: 717-26.
29. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13: 1211-8.
30. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 2008;105: 14342-6.
31. Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, et al. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol 1993;21: 1271-5.
32. Guhl S, Babina M, Neou A, Zuberbier T, Artuc M. Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells - drastically reduced levels of tryptase and chymase in mast cell lines. Exp Dermatol 2010;19: 845-7.
33. Koibuchi Y, Ichikawa A, Nakagawa M, Tomita K. Histamine release induced from mast cells by active components of compound 48/80. Eur J Pharmacol 1985;115: 163-70.
34. Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Tertilt C, Bopp T, et al. Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines. J Immunol 2006;177: 6667-74.
35. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4: 583-94.
36. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104: 777-85.
37. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194: 809-21.
38. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003;300: 1527-8.
39. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007;13: 3087-99.
40. Shinozaki S, Mashima H, Ohnishi H, Sugano K. IL-13 promotes the proliferation of rat pancreatic stellate cells through the suppression of NF-kappaB/TGF-beta1 pathway. Biochem Biophys Res Commun 2010;393: 61-5.
41. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12: 99-106.
42. Miller JS, Moxley G, Schwartz LB. Cloning and characterization of a second complementary DNA for human tryptase. J Clin Invest 1990; 86: 864-70.
43. Vanderslice P, Ballinger SM, Tam EK, Goldstein SM, Craik CS, Caughey GH. Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci U S A 1990;87: 3811-5.
44. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991;88: 493-9.
45. McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP. Tryptase/protease-activated receptor 2 interactions induce selective mitogenactivated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 2011;58: 264-70.
46. Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G. The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1alpha acts as a mast cell chemotaxin. Eur J Immunol 2000;30: 3614-22.
47. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002;527: 255-62.
48. Ahmed A, Powers MP, Youker KA, Rice L, Ewton A, Dunphy CH, et al. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathol Res Pract 2009;205: 634-8.
49. Chiu A, Nanaji NM, Czader M, Gheorghe G, Knowles DM, Chadburn A, et al. The stromal composition of mast cell aggregates in systemic mastocytosis. Mod Pathol 2009;22: 857-65.
50. Saika S, Saika S, Liu CY, Azhar M, Sanford LP, Doetschman T, et al. TGFbeta2 in corneal morphogenesis during mouse embryonic development. Dev Biol 2001;240: 419-32.
51. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98: 1806-18.
52. Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med 2008;358: 1860-1.
53. Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 2012;322: 169-76.
54. Palaniyandi Selvaraj S, Watanabe K, Ma M, Tachikawa H, Kodama M, Aizawa Y. Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull 2005;28: 2128-32.
55. Kim JH, Kolozsvary A, Jenrow KA, Brown SL. Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice. Radiat Res 2012;178: 202-6.